Calendario de eventos
Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors |
||||
|
||||
|
||||
Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors1 de junio de 2022 Organiza: National Hemophilia Foundation y Hemostasis Connect Ponente: Dra. Katharina Holstein |
JEvents v2.2.9 Copyright © 2006-2012